NuVasive Launches AttraX Scaffold Bone Graft

Register to receive a free Orthopedic Biomaterials Market Report Suite for US synopsis and brochure

San Diego, California-based NuVasive, Inc. has announced the U.S. launch of AttraX Scaffold, the company’s absorbent ceramic-collagen bone graft with an optimized surface.

According to the company, “Unlike traditional ceramic materials that do not by themselves generate bone formation when implanted in an intramuscular site, AttraX Scaffold has unique microstructure and microporosity that are optimized for bone formation in this environment. The AttraX surface technology, through its carefully defined and tightly controlled features at the submicron scale, drives the differentiation of mesenchymal stem cells into bone-forming osteoblasts without added growth factors.”

“Available in strips, blocks and morsels, AttraX Scaffold can be used in the posterolateral spine to promote fusion. AttraX Scaffold complements the currently marketed AttraX Putty product line to offer spine surgeons a suite of surface-optimized ceramic graft materials to meet surgical needs. During preclinical testing in posterolateral fusion (PLF) models, AttraX fusion rates were equivalent to or better than autograft, and faster than traditional ceramic grafts. In addition, spinal segments fused with AttraX had greater biomechanical strength than segments treated with ACTIFUSE ABX or Vitoss BA in a rabbit PLF model.”

Matt Link, executive vice president, strategy, technology and corporate development told OTW, “When developing a new biologic offering like AttraX Scaffold, so many of the details and performance indicators come out when the material is tested in vivo. For example, how it interacts with the body’s cells and tissues to form new bone is critical to its overall performance. The team was impressed and excited by how well AttraX Scaffold performed in preclinical testing, showing both increased bone formation and faster fusion compared to traditional ceramic materials.”

“We are delivering the only advanced bone grafting material for spine surgery that combines an absorbent collagen matrix for excellent intraoperative handling and a ceramic with optimized surface technology shown to promote bone growth without added growth factors.”


For Further Information

More on the orthopedic biomaterials market in the U.S. can be found in a series of reports published by iData entitled the U.S. Market Report Suite for Orthopedic Biomaterials. This report covers the following market segments: bone graft substitutes (which is represented by allografts, demineralized bone matrix, and synthetic bone grafts), orthopedic growth factors, cellular allografts, orthopedic cell therapy, hyaluronic acid viscosupplementation, orthopedic cartilage repair and spinal machined bone allografts

The iData series on the market for orthopedic biomaterials covers the U.S. and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. To find out more about orthopedic biomaterials market data or procedure data, register online or email us at for an U.S. Market Report Suite for Orthopedic Biomaterials brochure and synopsis.

Leave a Reply